Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tarsus Pharmaceuticals (TARS) Treasury Shares (2021 - 2025)

Historic Treasury Shares for Tarsus Pharmaceuticals (TARS) over the last 5 years, with Q3 2025 value amounting to $1.7 million.

  • Tarsus Pharmaceuticals' Treasury Shares fell 740.82% to $1.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.7 million, marking a year-over-year decrease of 740.82%. This contributed to the annual value of $1.9 million for FY2024, which is 1208.83% up from last year.
  • As of Q3 2025, Tarsus Pharmaceuticals' Treasury Shares stood at $1.7 million, which was down 740.82% from $1.8 million recorded in Q2 2025.
  • Over the past 5 years, Tarsus Pharmaceuticals' Treasury Shares peaked at $2.0 million during Q1 2024, and registered a low of $17251.0 during Q4 2021.
  • For the 5-year period, Tarsus Pharmaceuticals' Treasury Shares averaged around $1.5 million, with its median value being $1.7 million (2025).
  • In the last 5 years, Tarsus Pharmaceuticals' Treasury Shares surged by 309551.33% in 2022 and then plummeted by 740.82% in 2025.
  • Over the past 5 years, Tarsus Pharmaceuticals' Treasury Shares (Quarter) stood at $17251.0 in 2021, then soared by 3095.51% to $551258.0 in 2022, then surged by 209.97% to $1.7 million in 2023, then increased by 12.09% to $1.9 million in 2024, then dropped by 8.71% to $1.7 million in 2025.
  • Its last three reported values are $1.7 million in Q3 2025, $1.8 million for Q2 2025, and $1.9 million during Q1 2025.